Banner

Telomerase Activity in Diabetic Patients with Angiopathy

• 2014
العودة
معلومات البحث
المؤلفون 1Ayman El Badawy,1 Mohamed Shawky,1Amr M. ElHammady,1Mohamed El-Assal,1Ashraf Talaat ,1Ahmed M.Hussein, 1,2Khalid Belal
الكلمات المفتاحية telomerase, diabetic patients, angiopathy (micro- or macroangiopathy).
المجلة العلمية Not Available
الناشر Not Available
المجلد Not Available
العدد Not Available
الصفحات Not Available
publication.type International
رابط البحث Not Available
المواد المرفقة Not Available
الملخص
Diabetes mellitus (DM) is associated with damage to target organs and premature aging
and telomeres serve as a mitotic clock and biological marker of senescence. Aim of study: was to A) evaluate
telomerase activity in both type 1 and type 2 diabetic patients with microangiopathy and macroangiopathy, B) to
study the possible factors that affect the activity of this enzyme in these patients. Subjects and Methods: Study was
carried out on 40 patients from those attending diabetes clinics of Banha University Hospital, they were divided into
three groups: Group I: 10 type 1 diabetic patients with angiopathy (4males & 6 females). Group II: 10 type 2
diabetic patients with angiopathy (3males & 7females). Group III: 20 apparently healthy age & sex matched
volunteers serving as a control group. The following laboratory investigations were performed to all patients:
Plasma glucose (fasting and post prandial), Glycated hemoglobin, Lipogram (Total cholesterol, LDLc, HDLc and
Triglycerides), Serum creatinine, Urinary microalbumin and Study of telomerase activity in whole blood. Results:
Our results showed: that (HBA1C, microalbumin, creatinine, LDL, TG, TCH, PPBS and FBS)are significantly
higher in diabetic patients compared to control group where (telomeraseand HDL) are significantly lower in diabetic
patients compared to control group. Also, Telomerase activity was significantly low in diabetic patients with HbA1C
(≥7%), LDL-c (>100mg/dl), HDL-c (150mg/dl), TCH (>200mg/dl), microalbuminuria
(>30mg/ml) respectively compared to diabetic patients with HbA1C (